Sanofi-Aventis is seeking regulatory approval in Europe to market its new Soluvia™ influenza vaccine system that comprises an intradermal vaccine and a microneedle injector developed by BD.
Sanofi Pasteur conducted clinical trials on more than 7000 subjects to evaluate safety and the ability to generate an immune response of the novel intradermal (ID) influenza vaccine. Compared with intramuscular (IM) injection, ID delivery was shown to be especially effective in enhancing the immune response in the elderly1,2. Independently, BD conducted clinical trials involving more than 700 subjects and 3500 injections with BD Soluvia, and demonstrated that the system was safe and easy to use.3 Clinical testing showed that the BD microneedle is barely perceptible when it enters the skin and ensures the administration of the injected solution to the dermal layer irrespective of the subject’s gender, age, ethnicity and body mass.4
BD Soluvia is a prefillable microinjection system that is integrated with a tiny BD microneedle. It has been proven to offer a simple, reliable method of delivery. While most vaccines are injected into the muscle, the BD microneedle allows the vaccine to be accurately delivered intradermally — within the dermal layer of the skin. The dermal layer contains a dense network of lymphatic vessels feeding local lymph nodes, resulting in rapid and efficient access of the vaccine into the immune system. It also contains a high concentration of potent immune cells that play a key role to initiate the immune response following vaccination.
Press release: First European Application Filed for Product Using Innovative Intradermal Microinjection System BD Soluvia™…